Status : Published Published On : Dec, 2023 Report Code : VRHC1260 Industry : Healthcare Available Format : Page : 150
2025
2030

Global Imaging CRO Market – Analysis and Forecast (2025-2030)

Industry Insight by Service (Imaging Acquisition and Protocol Development, Application Design, Image Collection and QC, Digital Image Conversion, and Support and Maintenance), by Modality (Computed Tomography Scan, Magnetic Resonance Imaging (Diffusion Tensor Imaging, Functional MRI, Resting-State Functional Connectivity MRI, Volumetric MRI, and Arterial Spin Labeling for Quantitative Perfusion Imaging), Positron Emission Tomography (Positron Emission Tomography with 18F Isotope and Other PET), and Others), by Application (Oncology Imaging CRO, Ophthalmology Imaging CRO, Neurology Imaging CRO, Cardiology Imaging CRO, and Others), by End User (Pharmaceutical Companies, Biotechnology Companies, Medical Device Manufacturers, Contract Research Organizations, Academic and Government Research Institutes, and Others), and Geography (U.S., Canada, Germany, U.K., France, China, Japan, India, and Rest of the World)

Industry Overview

The Global Imaging CRO Market is anticipated to grow from USD 4.6 billion in 2023 to USD 8.8 billion in 2030, registering a CAGR of 7.1% during the forecast period 2025-2030. There is a massive transformation in the biopharmaceutical market and their manufacturing capabilities towards the healthcare industry during the last few years. There is an increased number of regulatory reforms within the industry which offer an improved outsourcing capability. CROs, imaging CROs, and contract development and manufacturing organizations (CDMOs) are enhancing the existing pharmaceutical, biotechnology, and medical device firms' quality, cost-effectiveness, and manufacturing capacity.

Imaging CRO Market Highlights

Furthermore, in order to boost their production, large pharmaceutical companies are expanding their manufacturing and purchasing capacity from smaller companies. Thus, the total market for imaging CROs is predicted to increase at a fast rate as pharmaceutical and biotechnology companies become more reliant on imaging CROs to outsource the medical imaging component of clinical trials studies. Imaging CROs play a crucial role in the development of new drugs and medical devices by offering expertise in medical imaging techniques and analysis. These organizations offer a range of services, including image acquisition, image interpretation, data management, and regulatory compliance. They work closely with pharmaceutical companies, biotechnology firms, academic institutions, and government agencies to support the imaging aspects of clinical trials, such as assessing the efficacy and safety of new treatments.

The COVID-19 pandemic has resulted in a huge rise in biopharmaceutical companies' spending on research and development. The development of vaccines and drugs for the treatment of SARS-CoV virus infection is involving researchers, scientists, and skilled personnel from all over the world, and this scenario is expected to directly boost demand for CROs for large-scale production in a shorter time frame, boosting the overall market for imaging CRO.

Market Segmentation

Insight by Service

Based on service, the global imaging CRO market is segmented into Imaging Acquisition and Protocol Development, Application Design, Image Collection and QC, Digital Image Conversion, and Support and Maintenance. Image acquisition and protocol development are anticipated to grow at a significant pace during the forecast period.  A protocol is the main document that specifies a clinical trial's goals, design, methods, statistical considerations, and organization. The protocol begins by outlining the study's background and justification before moving on to the trial's plan. This plan must be carefully constructed to protect the individuals' health and safety while also answering specific research questions. The protocol also serves an external purpose by offering a clear and comprehensive account of the study's processes, allowing others to fully comprehend the study's findings.

Insight by Modality

Based on modality, the global imaging CRO market is segregated into Computed Tomography (CT) Scan, Magnetic Resonance Imaging (MRI), Positron Emission Tomography (PET), and Others (X-Rays, Ultrasound, Scanning Laser Ophthalmoscopy (SLO), Optical Coherence Tomography, Scanning Laser Polarimetry (SLP), and Others. Magnetic Resonance Imaging (MRI) includes Diffusion Tensor Imaging (DTI), Functional MRI (fMRI), Resting-State Functional Connectivity MRI (fcMRI), Volumetric MRI (fMRI), Arterial Spin Labeling for Quantitative Perfusion Imaging (ASL). Positron Emission Tomography (PET) is further divided into Positron Emission Tomography with 18F Isotope (FDG-PET) and Other PET. The Computed Tomography segment is anticipated to have significant growth during the forecast period owing to its several benefits like the study of drug activity and screening of injuries, tumors, and abnormalities in the body. Also, the mounting funds and investment in the field of clinical research and clinical trials will propel the growth of the segment.

Insight by Application

Based on application, the global imaging CRO market is segmented into Oncology Imaging CRO, Ophthalmology Imaging CRO, Neurology Imaging CRO, Cardiology Imaging CRO, and Others. The oncology imaging CRO is anticipated to have a larger share during the forecast period owing to the rising cases of cancer leading to increased demand for new and developed treatment options. This will lead to a surge in clinical trials and a mounting need to outsource services used in trials. The neurology imaging CRO is anticipated to have the fastest growth during the projected period owing to the rising use of imaging in neurology clinical trials.

Insight by End-User

Based on end-user, the global imaging CRO market is classified into Pharmaceutical Companies, Biotechnology Companies, Medical Device Manufacturers, Contract Research Organizations (CRO), Academic and Government Research Institutes, and Others. The Contract Research Organisation contributes to the largest share in the market owing to the increased cost of drug development, increased expenditure on R&D activities. Contract research outsourcing alliances also provide cutting-edge services. As a result, government agencies prefer to delegate project management to CROs.

Global Imaging CRO Market Report Coverage

Report Metric

Details

Historical Period

2018 - 2023

Base Year Considered

2024

Forecast Period

2025 - 2030

Market Size in 2023

U.S.D.  4.6 Billion

Revenue Forecast in 2030

U.S.D.  8.8 Billion

Growth Rate

7.1%

Segments Covered in the Report

By Service, By Modality, By Application, and By End-User

Report Scope

Market Trends, Drivers, and Restraints; Revenue Estimation and Forecast; Segmentation Analysis; Impact of COVID-19; Companies’ Strategic Developments; Market Share Analysis of Key Players; Company Profiling

Regions Covered in the Report

North America, Europe, Asia-Pacific, Middle East, and Rest of the World

Industry Dynamics

Growth Drivers

The Imaging CRO market has experienced significant growth in recent years due to several factors:

Increasing Complexity of Clinical Trials: Many modern clinical trials require advanced imaging techniques, such as magnetic resonance imaging (MRI), computed tomography (CT), positron emission tomography (PET), and ultrasound. Imaging CROs provide the necessary expertise and infrastructure to handle these complex imaging requirements.

Regulatory Compliance: Regulatory authorities, such as the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA), have stringent guidelines for the use of medical imaging in clinical trials. Imaging CROs ensure compliance with these regulations, helping companies navigate the approval process smoothly.

Advancements in Imaging Technology: The rapid advancement of imaging technology has expanded the possibilities for using imaging data in clinical trials. Imaging CROs leverage these technological advancements to provide more accurate and detailed analysis, leading to better decision-making in drug development.

Cost and Time Efficiency: Outsourcing imaging services to specialized CROs can be more cost-effective and time-efficient for pharmaceutical companies compared to establishing in-house imaging capabilities. Imaging CROs offer a dedicated team of experts, specialized infrastructure, and streamlined processes.

Challenges

The massive installation costs of medical imaging systems which include procuring, housing, and maintaining equipment and high implementation barriers will impede the growth of the market. Furthermore, logistical and supply chain challenges may also hamper the growth of the global imaging CRO market.

Opportunities

The rising outsourcing trend in pharmaceutical companies along with automation in the imaging CRO process will create promising opportunities for the growth of the global imaging CRO market. The global Imaging CRO market is expected to continue growing in the coming years. Factors such as the increasing number of clinical trials, rising adoption of precision medicine approaches, and the need for more objective and quantitative imaging endpoints contribute to the market's expansion. Additionally, the growing focus on personalized medicine and the emergence of artificial intelligence and machine learning in medical imaging analysis are expected to further drive the demand for Imaging CRO services.

Geographic Overview

North America contributes the largest share in the imaging CRO market owing to the rising number of clinical trials which has increased the demand for imaging CROs so as to have reduced workload and is cost-effective. Furthermore, the end-users in the region are using developed imaging equipment and automation so to have efficient processing.

Competitive Insight

The industry players are adopting strategies like a novel product launch, M&A, partnerships, and collaborations to sustain their share and diversify the product portfolio.

Several multinationals are working with small-medium imaging CROs to grow their service offerings to customers all over the world. In order to improve the quality of outcomes from the manufacturing process in both research and clinical domains, the global imaging CRO market is likely to see more collaboration between CROs and pharmaceutical and biotechnology businesses. The overall revenue of the market is predicted to have strong incremental potential during the forecast period owing to a progressive move toward CROs for performing imaging trials.

Paraxel, as one of the world's top global clinical research organizations (CROs), has the clinical development capabilities and integrated consulting knowledge needed to simplify development at every stage – faster and more cost-effectively. Their therapeutic, technological, and functional competence is reinforced by a patient-first culture inherent in their DNA, from decentralized clinical trials to regulatory consulting services and exploiting real-world data.

WorldCare Clinical is a global imaging CRO that specializes in imaging in clinical studies and combines scientific experience, cutting-edge technology, and operational excellence to improve the precision and accuracy of blinded independent central assessment of Phase I–IV clinical trial data. WCC's collaboration with MGH and other Harvard Hospitals has grown to include Oncology, Neurology, Cardiology, Pathology, and Dermatology.

Recent Development by Key Players

In September 2021, the world's premier ophthalmology imaging core lab, Digital Angiography Reading Center (DARC), has been acquired by WorldCare Clinical (WCC), a worldwide imaging core lab situated in New York. Age-Related Macular Degeneration, Diabetic Retinopathy, Branch and Central Vein Occlusion, Choroidal Melanoma, Uveitis, PCV, and Retinitis Pigmentosa are just a few of the problems that DARC has studied.

In July 2021, ICON has completed the previously discussed acquisition of PRA Health Sciences, a contract research company, for a total price of roughly $12 billion. In February 2021, the firms agreed to merge, with ICON paying PRA shareholders $80 in cash per share and 0.4125 shares of its stock.

Key Players Covered in the Report

Some of the major players in the global imaging CRO industry are Parexel International Corporation, WORLDCARE CLINICAL, ICON plc, IXICO plc, The Micron Group, WuXi AppTec, Medpace, Labcorp Drug Development, Imaging Endpoints, and Radiant Sage LLC.

The Imaging CRO Market report offers a comprehensive market segmentation analysis along with an estimation for the forecast period 2023–2030.

Segments Covered in the Report

  • By Service
    • Imaging Acquisition and Protocol Development
    • Application Design
    • Image Collection and QC
    • Digital Image Conversion
    • Support and Maintenance
  • By Modality
    • Computed Tomography Scan
    • Magnetic Resonance Imaging
    • Diffusion Tensor Imaging
    • Functional MRI
    • Resting-State Functional Connectivity MRI
    • Volumetric MRI
    • Arterial Spin Labeling for Quantitative Perfusion Imaging
    • Positron Emission Tomography
    • Positron Emission Tomography with 18F Isotope
    • Other PET
    • Others
  • By Application 
    • Oncology Imaging CRO
    • Ophthalmology Imaging CRO
    • Neurology Imaging CRO
    • Cardiology Imaging CRO
    • Others
  • By End User
    • Pharmaceutical Companies
    • Biotechnology Companies
    • Medical Device Manufacturers
    • Contract Research Organizations
    • Academic and Government Research Institutes
    • Others

Region Covered in the Report

  • North America
    • U.S.
    • Canada
    • Mexico
  • Europe
    • Germany
    • U.K.
    • France
    • Italy
    • Spain
    • Russia
    • Rest of Europe
  • Asia-Pacific (APAC)
    • China
    • Japan
    • India
    • South Korea
    • Rest of Asia-Pacific
  • Rest of the World (RoW)
    • Brazil
    • Saudi Arabia
    • South Africa
    • U.A.E.
    • Other Countries

 

Imaging CRO Market Size and Market Analysis

To explore more about this report - Request a free sample copy

Frequently Asked Questions

The global imaging CRO market is anticipated to grow from USD 4.6 billion in 2023 to USD 8.8 billion in 2030, registering a CAGR of 7.1% during the forecast period 2025-2030.
Based on application, the global imaging CRO market is segmented into Oncology Imaging CRO, Ophthalmology Imaging CRO, Neurology Imaging CRO, Cardiology Imaging CRO, and Others.
The rising number of clinical trials, development in the pharmaceutical industry, mounting awareness towards process automation, increased demand for high precision in drug manufacturing, and growing dependence of biotechnology and pharmaceutical companies on the CROs to conduct imaging trials will propel the growth of the global imaging CRO market.
North America dominates the imaging CRO market owing to support from the government regarding favorable regulations and programs that will accelerate the growth.
Some of the major players in the global Imaging CRO market include Parexel International Corporation, WORLDCARE CLINICAL, ICON plc, IXICO plc, The Micron Group, WuXi AppTec, Medpace, Labcorp Drug Development, Imaging Endpoints, and Radiant Sage LLC.

Place an order

Research Methodology

  •  Desk Research / Pilot Interviews
  •  Build Market Size Model
  •  Research and Analysis
  •  Final Deliverabvle

CONNECT WITH OUR SALES TEAM